
Antiemesis: A comparison of Treatment Approach between NCCN and ASCO Guidelines
Diana Van Ostran, PharmD, BCOP

Contemporary Pharmacotherapy Management of High-grade Gliomas
Alyssa Strohbusch, PharmD, MS, CPh, BCOP

Pharmacotherapy Management in Chronic Lymphocytic Leukemia (CLL)
Tiba Al Sagheer, PharmD, BCOP, BCACP

Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC
Luis E. Raez, MD, FACP, FCCP

Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC
Luis E. Raez, MD, FACP, FCCP

Novel Mechanisms of Resistance Identified for Tyrosine Kinakse Inhibitors against ALk and Ros1 Tumors in NSCLC
Stephen Liu, MD
Displaying 1,276 - 1,300 of 2,875

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok